OpenLB
Open Library of Bioscience
Advanced Search
Clinical and translational medicine
Nov, 2020;10 (7): e224.

Persistent viral activity, cytokine storm, and lung fibrosis in a case of severe COVID-19.

Gang Xu, Yang Liu, Mingfeng Liao, Jizhou Gou, Xin Wang, Jing Yuan, Weilong Liu, Guangde Zhou, Shuye Zhang, Lei Liu, Zheng Zhang
Author Information
  1. Gang Xu: Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  2. Yang Liu: Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  3. Mingfeng Liao: Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  4. Jizhou Gou: Department for Pathology, Shenzhen Third People's Hospital, the Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  5. Xin Wang: Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  6. Jing Yuan: Department for Infectious Diseases, Shenzhen Third People's Hospital, the Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  7. Weilong Liu: Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  8. Guangde Zhou: Department for Pathology, Shenzhen Third People's Hospital, the Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  9. Shuye Zhang: Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  10. Lei Liu: Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  11. Zheng Zhang: Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China. ORCID
PMID: 33252859 DOI: 10.1002/ctm2.224

Abstract

No abstract text available.

References

  1. Lancet. 2020 Feb 15;395(10223):514-523 [PMID: 31986261]
  2. Nat Commun. 2020 Aug 6;11(1):3924 [PMID: 32764665]
  3. Lancet Respir Med. 2020 Apr;8(4):420-422 [PMID: 32085846]
  4. N Engl J Med. 2020 Feb 20;382(8):727-733 [PMID: 31978945]
  5. Lancet. 2020 Feb 15;395(10223):497-506 [PMID: 31986264]
  6. J Thorac Oncol. 2020 May;15(5):700-704 [PMID: 32114094]
  7. Am J Respir Crit Care Med. 2019 Jun 15;199(12):1517-1536 [PMID: 30554520]
  8. JAMA. 2020 Mar 17;323(11):1061-1069 [PMID: 32031570]
  9. Am J Respir Cell Mol Biol. 2016 Dec;55(6):759-766 [PMID: 27603223]

Grants

  1. 2019A1515011072/Natural Science Foundation of Guangdong Province,
  2. 81700540/National Natural Science Foundation of China,
Letter

Links to CNCB-NGDC Resources

GEN: GEND000429 (Identification of Lead Drug Candidates for COVID-19 based on Drug Screening Using Human Pluripotent Stem Cell-Derived Cells/Organoids)

Word Cloud

Similar Articles

Cited By